Resumen

FELICIANO-ALFONSO, John E. Rosuvastatin: Role in Cardiovascular High-risk Patient. rev.fac.med. [online]. 2013, vol.61, n.1, pp.41-51. ISSN 0120-0011.

Statins are the lipid-lowering drug family of first choice in situations of hypercholesterolemia or mixed dyslipidemia with predominant increase in cholesterol. The evidence shows conclusively that each one of the commercially available statins have proven benefits on outcomes of cardiovascular morbidity and mortality. However, rosuvastatin has certain pharmacokinetic efficacy and cost-effectiveness characteristics that make it an attractive molecule to be the statin of choice in patients at high cardiovascular risk.

Palabras clave : Hydroxymethylglutaryl-CoA Reductase Inhibitors; cardiovascular diseases; dyslipidemias; Cost-Effectiveness Evaluation.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )